Fiche publication
Date publication
février 2007
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MARTIN Laurent
Tous les auteurs :
Arveux P, Benard S, Bouee S, Lafuma A, Martin L, Cravello L, Remy V, Breugelmans JG
Lien Pubmed
Résumé
The objective of this study was to estimate the direct costs of invasive cervical cancer (ICC) management to the French national health insurance system the 1st year after ICC diagnosis. A retrospective survey was conducted in three centres in 2005, including 42 patients admitted for ICC between 2001-2003. Medical records were examined for data relating to treatments and to determine the management costs. To estimate the annual cost of ICC management in France, data were extrapolated to the general population. The number of new ICC cases in France was estimated at 3,24 7 in 2003. The mean hospitalisation cost increased with ICC severity at diagnosis : 9,164 euro for stage I, 15,999 euro for stage II, 22,69 7 euro for stage III, and 26,886 euro for stage IV The annual cost associated with the medical management of ICC patients was estimated at 43,862,125 euro (sensitivity range 32,973,461 euro - 54,748,422 euro) corresponding to a mean patient cost of 13,509 euro. Recent HPV vaccination studies have shown 100 916 for a quadrivalent (6,11,16,18) HPV vaccine against HPV-induced carcinoma in situ (FIGO stage 0/CIN3), a precursor lesion that may develop into ICC Thus. it is expected that this vaccine will significantly reduce the socio-economic burden associated with this disease.
Référence
Bull Cancer. 2007 Feb 1;94(2):219-24.
